CITY THERAPEUTICS, INC. — Form SCHEDULE 13D
Filed October 26, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, and individuals Keith Crandell, Robert Nelsen, Kristina Burow, and Steven Gillis executed a joint filing agreement dated October 26, 2026, pursuant to SEC Rule 13d-1(k)(1) for reporting beneficial ownership of City Therapeutics, Inc. shares. The filing itself contains no disclosure of share counts, ownership percentages, acquisition details, or transaction amounts—only the procedural agreement to file a single Schedule 13D statement.
Why this rating
Boilerplate joint filing agreement with no quantified ownership, transaction value, or strategic detail disclosed. Procedural only; substance unknown until main 13D filing.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.